^
    Apply
    Safety and Anti-leukemic Activity of Vodobatinib (K0706) for Treatment of Ph+ CML Resistant/Intolerant to ≥3 Prior CML Therapies (NCT02629692)
    Phase 1/2
    Sun Pharma Advanced Research Company Limited
    Active, not recruiting
    Last update posted :
    10/27/2023
    Initiation :
    04/25/2017
    Primary completion :
    08/01/2026
    Completion :
    08/01/2026
    ABL1 • BCR
    |
    vodobatinib (SCO - 088)